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BACKGROUND: Prostate-specific antigen (PSA) screening for prostate cancer has high risks of overdiagnosis, particularly among older
men, and reports from screening trials indicate that it saves few lives after 11 to 13 years of follow-up. New clinical guidelines recommend
against PSA screening for all men or for men aged >70 years, but, to the authors’ knowledge, the expected population effects of these
guidelines have not been studied to date. METHODS: Two models of prostate cancer natural history and diagnosis were previously
developed using reconstructed PSA screening patterns and prostate cancer incidence in the United States. Assuming a survival bene-
fit of PSA screening consistent with the screening trials, the authors used the models to predict incidence and mortality rates for the
period from 2013 through 2025 under continued PSA screening and under discontinued PSA screening for all men or for men aged
>70 years. RESULTS: The models predicted that continuation of recent screening rates will overdiagnose 710,000 to 1,120,000 men
(range between models) but will avoid 36,000 to 57,000 cancer deaths over the period 2013 through 2025. Discontinued screening
for all men eliminated 100% of overdiagnoses but failed to prevent 100% of avoidable cancer deaths. Continued screening for men
aged <70 years eliminated 64% to 66% of overdiagnoses but failed to prevent 36% to 39% of avoidable cancer deaths. CONCLU-
SIONS: Discontinuing PSA screening for all men may generate many avoidable cancer deaths. Continuing PSA screening for men
aged <70 years could prevent greater than one-half of these avoidable cancer deaths while dramatically reducing overdiagnoses
compared with continued PSA screening for all ages. Cancer 2014;120:3519-26. VC 2014 American Cancer Society.
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INTRODUCTION
Prostate cancer is the most common solid organ cancer in men in the United States, with an estimated 233,000 new cases
and 29,480 deaths expected in 2014.1 The high incidence of prostate cancer reflects a combination of the high latent prev-
alence of disease2 and the effects of prostate-specific antigen (PSA) screening. Widespread adoption of PSA screening be-
ginning in 1987 led to a doubling of incidence rates and significantly reduced the occurrence of metastatic cancer at the
time of presentation.3 However, the role of PSA screening in the 56% decrease in prostate cancer mortality rates noted
since 19914 remains controversial. The US-based Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial
found no reduction in mortality after 13 years of follow-up.5 In contrast, the European Randomized Study of Screening
for Prostate Cancer (ERSPC) trial found a significant 20% relative reduction in mortality after 11 years of follow-up, but
this amounted to an absolute reduction of only 1 death per 1000men screened.6 Although the long-termmortality benefit
of PSA screening is uncertain, it may exceed that reported for the trials to date.7,8
Counterbalancing mixed reports of benefit, the harms of PSA screening are significant. In the United States, 23% to
42% of PSA-detected cancers would never have been detected in the absence of screening9; by definition, treating these
overdiagnosed cancers cannot improve patient outcomes and often leads to erectile, urinary, and bowel dysfunction.10-12
Although cancers detected in young men with high PSA levels and a high Gleason score are unlikely to be overdiag-
nosed,13 a majority of cancers are found in older men with low-risk characteristics.
Concerns regarding high rates of overdiagnosis and overtreatment and small absolute numbers of cancer deaths pre-
vented by screening in trial reports led the US Preventive Services Task Force to recommend against routine PSA screening
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for all men.14 Other organizations, such as the American
Cancer Society,15 the American Urological Association,16
and the American College of Physicians,17 advise shared
decision-making for men aged <70 years with at least a
10-year life expectancy. An upper age limit for screening
was motivated partly by the age group found to benefit
from screening in the ERSPC trial and partly because of
higher risks of overdiagnosis and uncertain treatment ben-
efit among older men.18-21
In this article, we quantified expected population
effects of these new PSA screening guidelines using 2
models of prostate cancer natural history. The models are
statistical representations of disease progression, detec-
tion, treatment, and survival that were previously devel-
oped to study the plausible roles of PSA screening22 and
changes in initial treatments23 in prostate cancer mortality
trends. Because the models separate prostate cancer natu-
ral history and nonscreen diagnosis from detection by
PSA screening, they provide a coherent framework for
predicting the plausible effects of discontinued screening.
We consider perfect adherence to these new guidelines
and the continuation of contemporary disease manage-
ment patterns as a reasonable (albeit idealized) substrate
for evaluating expected impacts on prostate cancer inci-
dence and mortality patterns.
MATERIALS AND METHODS
Prostate Cancer Natural History
The 2 models of prostate cancer natural history and diag-
nosis24,25 used in the current study were independently
developed as part of the Cancer Intervention and Surveil-
lance Modeling Network (CISNET), a consortium of
investigators using surveillance models to investigate driv-
ers of national cancer trends. Numerous statistical models
have produced various estimates of prostate cancer out-
comes associated with PSA screening, but many do not
readily generalize beyond the particular setting to which
they were applied. The CISNET prostate cancer models
were designed to use population-based data sources to dis-
entangle disease natural history and nonscreen diagnosis
from the effects of PSA screening. In this way, the esti-
mated models represent a virtual laboratory for assessing
the expected impacts of alternative screening PSA scenar-
ios, such as discontinued screening. By using 2 models, we
were able to examine the sensitivity of the results to natu-
ral history assumptions.
Figure 1 illustrates prostate cancer natural history
(health states and transitions between states, representing
the onset of a screen-detectable cancer, disease progression
through stages and/or grades, and clinical presentation) in
the 2 models. In the Fred Hutchinson Cancer Research
Center (FHCRC) model, cancers are localized at onset
and may be either low grade (Gleason score of 2-7) or
high grade (Gleason score of 8-10). Risks of metastasis
and diagnosis depend on patient age, time since onset,
and tumor stage and grade and are correlated with indi-
vidual PSA levels. In the University of Michigan
(UMICH) model, cancers can be localized or metastatic
and low grade or high grade at onset, and risks of stage
and grade progression and diagnosis depend on patient
age, year, time since onset, and tumor stage and grade (see
online supporting information for detailed model descrip-
tions). Screening according to reconstructed PSA screen-
ing patterns in the United States26 is superimposed on
each model to produce screen-detected and non–screen-
detected cases diagnosed each year.
The models were informed with the same prostate
cancer incidence data from the Surveillance, Epidemiol-
ogy, and End Results (SEER) program. The FHCRC
model also used PSA test results from the control arm of
the Prostate Cancer Prevention Trial27 to estimate PSA
growth rates and data regarding biopsy practice pat-
terns25,28 to model disease detection when the PSA level
Figure 1. Health state transitions are shown in 2 models of
prostate cancer natural history. Screen-detectable cancers in
both models progress from locoregional to distant stage. In
the University of Michigan model, cancer can also progress to
distant-stage disease before becoming screen detectable
(horizontal dashed gray arrows). Tumor grade (Gleason score
of 2-7 or 8-10) is fixed in the Fred Hutchinson Cancer
Research Center model but lower-grade disease can progress
to higher grade in the University of Michigan model (vertical
dashed gray arrows).
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exceeds 4 ng/mL, whereas the UMICH model estimated
effective test sensitivity using SEER incidence and US
screening patterns. Risks of disease onset, progression,
and nonscreen diagnosis were estimated so that the mod-
els reproduced prostate cancer incidence rates in the
SEER program by age (50-84 years), calendar year (1975-
2000), stage of disease (locoregional or distant), and
tumor grade (Gleason score of 2-7 or 8-10). Estimation
details are provided in the online supporting information.
Treatment Benefit and Prostate Cancer Survival
To project prostate cancer survival after diagnosis, the
models used frequencies of conservative management,
radical prostatectomy, and radiotherapy from SEER and
frequencies of androgen deprivation therapy (ADT) from
the Cancer of the Prostate Strategic Urologic Research
Endeavor29 database.
In the absence of screening, patients assigned to con-
servative management or ADT monotherapy were
assumed to have baseline prostate cancer survival similar
to that for untreated cases in SEER from 1983 through
1986, just before PSA screening began. We assumed that
contemporary patients who were not detected by screen-
ing and who receive active surveillance have similar sur-
vival. To the best of our knowledge, there are no
randomized trials to date comparing the main primary
treatment options; based on a recent observational
study,30 we assumed that radical prostatectomy and radio-
therapy with ADT are similarly efficacious and that these
treatments are more efficacious than radiotherapy alone.
Patients assigned to radical prostatectomy (or radiother-
apy with ADT) had improved survival based on the Scan-
dinavian trial of radical prostatectomy versus watchful
waiting (hazard ratio [HR], 0.62)31 and consistent with
the US-based Prostate Cancer Intervention Versus Obser-
vation Trial.32 Patients assigned to radiation monother-
apy had survival that improved during the early 1990s
(HR of 0.9 before 1990, linear improvement to an HR of
0.7 in 1995, and constant thereafter)23 to reflect the
increase in radiation dose intensity over time.
Screening Benefit
A patient who is diagnosed by screening and would have
died of the disease in the absence of screening was
assumed to have prostate cancer survival and initial treat-
ment corresponding to the earlier age of the patient, stage
of disease, and/or tumor grade at the time of screen detec-
tion. This “stage-shift” effect of screening was previously
shown to be consistent with the mortality reduction
observed in the ERSPC trial after 11 years of follow-up
using the FHCRCmodel.33
In this study, both models used flexible representa-
tions of the stage-shift effect. Instead of giving a full stage-
shift to all cancers detected early by screening, a parameter
controls the scale of the benefit, with cancers that are
detected later in their natural history receiving less benefit.
Flexible stage-shift effects and parameter estimation
details are given in the online supporting information.
Predicted effects of PSA screening on prostate cancer
mortality are based on applying estimated stage-shift effects
to prostate cancer survival over a lifetime horizon for the
US population. In practice, the models independently gen-
erate prostate cancer survival (with any early detection and
treatment benefit) and other-cause survival from US life
tables.34 Actual survival is the shorter of these competing
survival times, with cause of death assigned accordingly.
Discontinued Versus Age-Restricted Screening
To quantify the expected effects of the new PSA screening
guidelines, we predicted prostate cancer incidence,
including overdiagnoses and distant-stage cancers, and
mortality under 3 scenarios: a continuation of recent
screening patterns (continued), a continuation of recent
screening patterns restricted to men aged <70 years (age-
restricted), and discontinued screening for all ages (dis-
continued). Recent PSA screening patterns are based on a
reconstruction using SEER-Medicare and National
Health Interview Survey data in 200026 and updated
using National Health Interview Survey data in 2005 and
2010. The incidence of overdiagnosis reflects patients
diagnosed by PSA screening who would not have been
diagnosed in the absence of screening (ie, who would have
died of other causes before clinical presentation). Prostate
cancer mortality after 2010 assumes that the distribution
of initial therapies remains constant as observed in 2010.
Predictions are for men aged 50 to 84 years between Janu-
ary 1, 2013, and December 31, 2025.
To inflate predictions for the SEER population to
the US population, incidence and mortality rates were
multiplied by US Census projections by 5-year age group
and calendar year.35
Model Validations
As a partial validation of the natural history models, we
compared predicted and observed incidence counts from
SEER in the year 2010 (ie, a decade later than the data
used to estimate the models). General agreement would
suggest that 1) the models reflect reasonable approxima-
tions to natural history and 2) there have not been
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significant changes in prostate cancer epidemiology or
practices related to prostate cancer diagnosis since the year
2000.
As a partial validation of the survival benefit of early
detection and treatment, we compared predicted and
observed absolute mortality reductions in simulations of
the ERSPC trial through 11 years of follow-up based on
stage-shift effects calibrated to match relative mortality
reductions. General agreement would suggest that the
models reflect reasonable approximations to prostate can-
cer survival, benefits of early detection and treatment, and
competing risks of other-cause death.
Sensitivity Analysis
Because some have argued that the lack of screening bene-
fit reported in the PLCO trial reflects at best a more mod-
est impact of early detection in the United States,36,37 we
also predicted the effects of screening on prostate cancer
mortality assuming reduced efficacy. The models recali-
brated stage-shift effects of screening to yield a 15% mor-
tality reduction compared with no screening after 11 years
of follow-up in simulated ERSPC trials, which is approxi-
mately one-half of the 29% reduction reported after cor-
rection for noncompliance.6 The models then projected
mortality rates under continued, age-restricted, and dis-
continued PSA screening assuming this reduced benefit.
RESULTS
Model Validations
Figure 2 illustrates prostate cancer incidence rates
reported in SEER and projected by the models for the cal-
ibration (1975-2000) and validation (2001-2010) years
(see online supporting information for comparisons by
patient age and stage of disease). The models closely ap-
proximate observed trends in locoregional and metastatic
incidence before and after the introduction of PSA screen-
ing through 2010. Figure 2 also shows corresponding
mortality rates; the models project constant mortality in
the absence of screening or changes in initial treatments
and similar reductions due to these interventions.
Table 1 presents a snapshot of localized cases, meta-
static cases, and prostate cancer deaths reported in SEER
and projected by the models in 2010. Both models over-
projected localized cases, although discrepancies were
Figure 2. Historical prostate cancer incidence and mortality rates, modeled effects of historical prostate-specific antigen (PSA)
screening, and model predictions are shown under 3 PSA screening policies: A) continuation of recent PSA screening patterns
(continued); B) continuation of recent PSA screening patterns restricted to men aged <70 years (age-restricted); and C) discon-
tinued PSA screening for all men (discontinued). Rates are age-standardized per 100,000 men aged 50 to 84 years. FHCRC indi-
cates Fred Hutchinson Cancer Research Center; UMICH, University of Michigan.
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relatively modest (2.0% for FHCRC vs 2.3% for
UMICH) over the period 2005 through 2010. The mod-
els estimated that 3 out of 4 cases were detected by PSA
screening in 2010, of which 25% to 38% (range between
models) were overdiagnosed. The models agreed that
screening explains nearly all of the decrease in metastatic
cases, and the calibrated stage-shift effects of screening
explain 48% to 52% of the observed drop in prostate can-
cer deaths compared with no screening.
In simulated ERSPC trials after 11 years of follow-
up, both models approximated the relative mortality
reduction of 29% after correction for nonattendance esti-
mated by trial investigators6 (29% for FHCRC vs 28%
for UMICH) and modestly overprojected the observed
absolute mortality reduction of 1.1 per 1000 men
screened (1.7 for FHCRC vs 1.5 for UMICH),6 most
likely because they did not account for nonattendance or
contamination in the actual trial.38
Overall, the correspondence between model projec-
tions and empirical data supports using the models to
investigate the plausible effects of new PSA screening poli-
cies. However, to account for factors not in the models
that contributed to the declines in distant-stage incidence
and mortality, we quantified the unexplained portions of
the declines in 2010 and subtracted these differences from
model projections in subsequent years. In other words, we
assumed that other factors that contributed to the
observed declines in 2010 would remain constant into the
future.
Primary Analysis
Figure 2 also illustrates prostate cancer incidence and
mortality rates predicted by the models under continued,
age-restricted, and discontinued PSA screening for the pe-
riod 2013 through 2025. The models predicted immedi-
ate declines in localized incidence rates under age-
restricted and discontinued screening, with steady
increases accumulating over this period. In both models,
incidence rates nearly returned to pre-PSA levels by the
year 2025 under discontinued screening. Mortality rates
also increased under age-restricted and discontinued
screening, with significantly faster increases noted under
discontinued screening. However, mortality rates did not
return to pre-PSA levels due to the continuation of con-
temporary patterns of initial treatments and other factors
contributing to the observed decline in mortality by 2010.
Table 2 reports localized cases, metastatic cases, and
prostate cancer deaths under each PSA screening scenario
for the period 2013 through 2025. Under continued
screening, the models projected 710,000 to 1,120,000
overdiagnosed cases and approximately 130,000 meta-
static cases at the time of presentation. Age-restricted
screening was found to prevent 470,000 to 720,000 over-
diagnoses (64%-66% decrease) but added 58,000 to
73,000 metastatic cases at the time of presentation (46%-
57% increase). In contrast, discontinued screening was
found to eliminate all overdiagnoses but more than
doubled metastatic cases at the time of presentation. The
models project >280,000 prostate cancer deaths through
2025 under continued screening. Age-restricted screening
added 13,000 to 22,000 prostate cancer deaths (5%-8%
increase) whereas discontinued screening added 36,000 to
57,000 prostate cancer deaths (13%-20% increase).
In summary, the models concurred that age-
restricted screening appears to substantially reduce over-
diagnoses while preventing a majority of the additional
metastatic cases at the time of presentation and prostate
cancer deaths predicted under discontinued screening.
Sensitivity Analysis
Under reduced PSA screening efficacy, age-restricted
screening added 6,000 to 14,000 prostate cancer deaths
(2%-5% increase), whereas discontinued screening added
18,000 to 35,000 prostate cancer deaths (6%-12%
increase). As in the primary analysis, age-restricted screen-
ing was found to prevent a majority of the additional
TABLE 1. Prostate Cancer Cases and Deaths Ex-
trapolated From SEER and Effects of Historical




Overdiagnoses — 65,500 41,300
Early detections — 104,900 126,100
Clinical detections — 51,000 53,700
Total 202,500 221,400 221,100
Metastatic cases
Prediction under no screening — 24,300 25,100
Effect of screening — 214,600 215,400
Effect of other factors (not modeled) — 21,400 21,400





Effect of treatment — 24,000 23,100
Effect of screening — 25,400 27,100
Effect of other factors (not modeled) — 26,100 26,500
Total 18,100 18,100 18,100
Abbreviations: FHCRC, Fred Hutchinson Cancer Research Center model;
PSA, prostate-specific antigen; SEER, Surveillance, Epidemiology, and End
Results program registries; UMICH, University of Michigan model.
a Counts are for US men aged 50 to 84 years.
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prostate cancer deaths predicted under discontinued
screening.
DISCUSSION
In the last 2 years, there have been major revisions to pros-
tate cancer screening policy recommendations by influen-
tial US guidelines panels, most notably the US Preventive
Services Task Force.14,39 Motivated largely by the results
of the PLCO and ERSPC trials, the new recommenda-
tions are generally conservative and advocate the cessation
of routine PSA screening for all men or for men aged>70
years or those with a limited life expectancy. The response
to these recommendations in terms of clinical practice is
evolving, but screening rates could decline dramatically.
The results of the current analysis suggest that discontin-
ued screening could have profound consequences for
prostate cancer deaths and advanced disease in the United
States.
The continuation of current screening is expected to
overdiagnose as many as 1 million US men but prevent
large numbers of metastatic cases at the time of presenta-
tion and prostate cancer deaths by 2025. Discontinued
screening indiscriminately eliminates both the harms and
benefits of screening; for example, it eliminates the over-
diagnosis and overtreatment of men with low-risk prostate
cancer but at great cost. Restricting screening to men aged
<70 years eliminates a majority of overdiagnosed cases
and preserves >50% of the metastatic cases avoided and
lives saved with contemporary screening patterns; this
finding is insensitive to whether screening efficacy is simi-
lar to or lower than that reported in the ERSPC trial.
The models confirm that PSA screening generates
substantial numbers of overdiagnosed cases, but the esti-
mates are below other reported figures,40 which were
based on coarse approximations with limited accounting
for patient age or period effects.41 The wide range for
the absolute number of overdiagnoses predicted by the
2 models is not unexpected given that this harm is not
directly observable and estimates are sensitive to
unknown aspects of prostate cancer natural history. In
particular, the UMICH model estimated fewer over-
diagnoses and more early detections than the FHCRC
model because its allowance for faster cancer progression
during the screen-detectable window implies shorter
lead times.42 Nonetheless, the reduction in overdiagno-
ses expected under age-restricted PSA screening relative
to discontinued PSA screening is highly consistent
between models.
The current study results confirmed that if screening
improves survival by a “stage-shift” effect, then PSA
screening appears to have played an important role in the
observed decline in prostate cancer mortality. However,
screening and changes in primary treatments do not
explain the entire observed decline in prostate cancer mor-
tality. Other factors, such as increasing obesity rates43 or
decreasing smoking rates,44 or other interventions such as
TABLE 2. Prostate Cancer Cases and Deaths Predicted by 2 Models Under 3 PSA Screening Policies: A)
Continuation of Recent PSA Screening Patterns (Continued), B) Continuation of Recent PSA Screening
Patterns Restricted to Men Aged <70 Years (Age-Restricted), and C) Discontinued PSA Screening for All
Men (Discontinued) for the Period 2013 Through 2025a







FHCRC UMICH FHCRC UMICH FHCRC UMICH FHCRC UMICH
Localized cases
Screen detections
Overdiagnoses 1,122,900 705,200 399,700 237,100 0 0 64.4 66.4
Early detections 1,763,600 2,071,400 1,130,000 1,163,900 0 0 35.9 43.8
Clinical detections 795,600 890,900 1,008,800 1,216,900 1,372,400 1,679,500 37.0 41.3
Total 3,682,100 3,667,400 2,538,400 2,617,800 1,372,400 1,679,500 49.5 52.8
Metastatic cases 127,900 129,300 186,200 202,600 271,100 291,300 40.7 45.3
Prostate cancer deaths
Base case PSA efficacy 283,500 284,600 296,400 306,900 319,400 342,000 35.9 38.9
Reduced PSA efficacy 284,300 285,400 290,300 299,400 301,800 320,700 33.9 39.6
Abbreviations: FHCRC, Fred Hutchinson Cancer Research Center model; PSA, prostate-specific antigen; UMICH, University of Michigan model.
a Counts are for US men aged 50 to 84 years.
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treatment at the time of biochemical recurrence45 might
have reduced mortality. The results of the current study
assumed the unexplained contribution of these factors to
the decline in mortality in 2010 will remain constant.
Provided these factors do not interact with the effects of
screening, they should not affect our main results.
The status quo of widespread relatively late screen-
ing46 irrespective of life expectancy47 and nearly universal
treatment29 clearly is far from optimal. Nevertheless, as
the current analysis demonstrated, wholesale abandon-
ment of screening efforts may be a costly solution.
Although an age-restricted policy is a compelling
improvement, it does not account for life expectancy or
screening history; a 66-year-old healthy man with no prior
PSA exposure faces a very different risk profile than a
counterpart with multiple comorbidities and multiple
prior PSA levels <1 ng/mL.48,49 Other screening strat-
egies may yield more favorable harm-benefit tradeoffs,33
particularly when combined with the greater use of active
surveillance.50
We accounted for key sources of uncertainty by
using 2 models of prostate cancer natural history and a
sensitivity analysis to screening benefit. Nonetheless,
other sources of uncertainty remain. Despite relying on
population-based data sets and conditioning effects of
interventions on patient and tumor characteristics, the
varied populations and settings in certain data sources
may not be perfectly compatible with each other or repre-
sentative of the general US setting. Restriction to coarse
grade categories (Gleason scores 2-7 vs 8-10) was neces-
sary to avoid bias due to upward grade migration over
time. We also did not incorporate life expectancy when
selecting men to be screened in the models, but it is likely
that men who choose to be screened for prostate cancer
are healthier than the general population. Therefore, our
estimates of overdiagnoses under screening may be mod-
estly inflated. Finally, we previously demonstrated that,
due to widespread contamination and lower-than-
expected mortality, the stage-shift effect of screening is
neither supported nor contradicted by results from the
PLCO trial.51 Nevertheless, the screening benefit in our
primary analysis has not been confirmed over the long-
term.
Recently revised screening guidelines are poised to
yield a significant shift in prostate cancer epidemiology,
reducing overdiagnosis and overall incidence at the
expense of increasing the burden of prostate cancer metas-
tasis and mortality. The current study projections indicate
that discontinuing screening may significantly erode
observed reductions in prostate cancer mortality over a
relatively short time frame. Continuing screening but
restricting it to men aged <70 years is one approach that
could preserve many of the benefits of contemporary pat-
terns of screening while still reducing harms. Rather than
abandoning screening entirely, the results of the current
study support finding ways to continue screening that
mitigate harm while preserving as much of the benefit as
possible.
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